18F-FDG PET/CT Metabolic Parameters and HER2 Expression in Colorectal Cancer

Ziyi Yang

Department of Nuclear Medicine, Fudan University Shanghai Cancer Center

Shuai Liu

Department of Nuclear Medicine, Fudan University Shanghai Cancer Center

Yuyun Sun

Department of Nuclear Medicine, Fudan University Shanghai Cancer Center

Junyan Xu

Department of Nuclear Medicine, Fudan University Shanghai Cancer Center

Jinjin Jiang

Department of Nuclear Medicine, Fudan University Shanghai Cancer Center

Xiaoxi Ma

Department of Pathology, Fudan University Shanghai Cancer Center

Yingjian Zhang

Department of Nuclear Medicine, Fudan University Shanghai Cancer Center

Shaoli Song (✉ shaoli-song@163.com)

Fudan University Shanghai Cancer Center

Original research

Keywords: 18F-FDG PET-CT; SUVmax; HER2; colorectal cancer

Posted Date: February 28th, 2020

DOI: <https://doi.org/10.21203/rs.2.24835/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Neoplasma on May 17th, 2021. See the published version at https://doi.org/10.4149/neo_2021_200803N807.

Abstract

Purpose: The relationship between ^{18}F -FDG uptake and HER2 expression in colorectal cancer has not been investigated yet. This study aimed to investigate the predictive efficiency of preoperative ^{18}F -FDG PET/CT for HER2 expression and prognosis in colorectal cancer.

Results: Over all 131 colorectal cancer patients, there were 27 (20.6%) patients were HER2 positive. SUVmax of primary tumor (Mean $\pm$ SD) in HER2-positive and HER2-negative group was 18.238 ± 8.912 and 14.455 ± 6.531 , respectively. SUVmax in HER2-positive group were higher than in negative group ($p = 0.034$). When the cutoff was based on 5cm, tumor size demonstrated significant positive correlations with SUVmax ($p = 0.012$) and HER2 expression ($p = 0.014$). Multivariate analysis showed that both SUVmax and tumor size had significant correlation with HER2 expression ($p = 0.049$ vs $p = 0.043$, respectively). In addition, statistical analysis showed that patients with higher SUVmax had better PFS ($p = 0.029$). There was no statistical difference of PFS between HER2-positive and HER2-negative group ($p = 0.28$).

Conclusion: ^{18}F -FDG metabolic parameters had significant correlation with HER2 expression in colorectal cancer. SUVmax combined with primary tumor size were better for predicting the HER2 status of colorectal cancer.

Background

Colorectal cancer (CRC) is one of the most commonly diagnosed cancer all over the world(1),although its epidemiology is obviously different in various regions. Accounting for an evaluated more than 49,000 deaths in the United States in 2016, CRC is also the third leading cause of cancer-related mortality(2). In China, CRC has the fifth highest incidence among all cancers in men and the fourth in women, and the fifth highest mortality in both men and women(3). At the initial diagnosis, approximately 25% of CRC patients present with metastases and a further 50% of patients will develop metastases(4). Surgery is still the most common treatment. However, treatment outcomes for colorectal cancer remain unsatisfactory in patients with inoperable or metastatic disease. Although new cytotoxic and molecularly targeted agents have improved the overall survival of CRC patients with metastases over the past two decades, but the rate of recurrence and failure remains high(5). Therefore, effective therapeutic regimens for such patients need to be identified and developed.

Previous studies have shown that 5.2% – 47.4% of patients with colorectal cancer are positive for human epidermal growth factor receptor 2 (HER2)(6–8). The HERACLES-A and MyPathway studies demonstrated that patients with HER2 amplification did not derive a survival benefit from chemoradiation therapy whereas patients without HER2 amplification derived a statistically significant survival benefit(9, 10). Therefore, it is important to identify clinical characteristics that might be predictive of HER2 status. Although there're some practices to determine HER2 expression in colorectal cancer patients, the procedures are invasive. Alternative noninvasive strategies, such as PET/CT, for predicting the mutation

profile would therefore be of great value. Several studies have demonstrated that PET/CT has the potential to predict the phenotype of a tumor(11–14), such as the HER2 status in gastric cancer(11) and the KRAS status in colorectal cancer(14). ^{18}F -FDG PET/CT has been widely used for diagnosis, monitoring of treatment response, surveillance, and prognostication in a variety of cancers(15, 16).

However, the relationship between ^{18}F -FDG uptake and HER2 expression in colorectal cancer, and the possible underlying mechanisms, are not clear. The present study aimed to investigate whether HER2 expression is associated with ^{18}F -FDG uptake and whether ^{18}F -FDG PET/CT can be used to predict the HER2 status and prognosis of colorectal cancer. To our knowledge, this was the first study to present evidence of the potential value of ^{18}F -FDG PET/CT scans for this use and to suggest that ^{18}F -FDG PET/CT may play a key role in determining the strategy for colorectal cancer patients by predicting their response to anti-HER2 antibody therapy.

Methods

Clinicopathological data

131 CRC patients(84 men and 47 women; age ranged from 30 to 85y) Undergoing ^{18}F -FDG PET/CT scans before surgical resection were obtained from shanghai cancer center Fudan University between May 2015 and August 2018. Those who had received any chemotherapy, radiation therapy, or molecular targeted therapy before ^{18}F -FDG PET/CT scans were excluded. Every patient had been operated surgery at the primary colorectal lesion after the specified check and the final pathology was colorectal adenocarcinoma or mucinous adenocarcinoma. Immunohistochemical results also had been received. Complete case records, including data on age, sex, tumor size, T stage, lymphatic metastasis were available. 131 patients met these criteria and gave written informed consent to participate in this retrospective study. This study protocol was approved by the institutional review board of shanghai cancer center, and all patients provided their consent for data handling.

^{18}F -FDG PET/CT protocol and imaging interpretation

^{18}F -FDG PET/CT scans were performed using a combined PET/CT scanner (Siemens Medical Systems, Biograph 16 HR). All patients fasted for at least 6 h before ^{18}F -FDG administration and glucose levels in the peripheral blood were confirmed to be 10 mmol/L or less before the ^{18}F -FDG injection (7.4 MBq/kg (0.2 mCi/kg) of body weight) in this study. Data acquisition that scanning included the area from the upper thigh to the skull started approximately 1 h after the injection and the low-dose CT scans were obtained with the following parameters: 40–60 mA, 120 kV, 0.6-s tube rotation, and 3.75-mm section thickness. For quantitative analysis, ^{18}F -FDG accumulation on a workstation were assessed by two experienced nuclear medicine physicians through calculating the standardized uptake value (SUV), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in the regions of interest placed over the

suspected lesions and the normal liver. SUV was calculated in a pixel as (radioactivity) / (injected dose/body weight). TLG was calculated as (mean SUV) x (MTV), in which MTV was measured with setting a margin threshold as SUV of 2.5. All values of SUVmax, MTV, and mean SUV were automatically measured by the analysis software for each lesion. For evaluating metastatic CRC, the highest SUV in a metastatic tumor was taken as SUVmax and the mean SUV was taken as SUVmean.

Immunohistochemical Analysis

Unlike in breast and gastric cancers, the criterion to define HER2-positive testing in CRC has not been standardized yet and has widely varied among different studies(9, 17, 18). In our study, Immunohistochemical analysis was performed on paraffin-embedded colorectal cancer tissues after microtome sectioning and staining using standard procedures. Positivity for HER2 was independently examined using light microscopy by 2 experienced pathologists. Circumferential membrane-bound staining of Human epidermal growth factor receptor 2 (HER2) was evaluated as 0, 1+, 2+, or 3+, in keeping with panel recommendations on HER2 scoring. Positivity (HER2) was considered with a score of 2 + or 3 + and negativity (HER2) with a score of 0 or 1+(11). The HER2 antibodies used were from A0485, polyclonal rabbit antibody.

Statistical Analysis

Statistical analysis was performed using SPSS software (version 21.0; SPSS, IBM Inc., Armonk, New York, USA). All continuous variables are expressed as mean $\pm$ SD. The relationship between clinicopathological characteristics and SUVmax was tested by t-test. Chi-square test was used for univariate analysis, and Logistic regression analysis for multivariate analysis to evaluate the preoperative predictors for HER2 expression. ANOVA way was used for the predictive efficiency of stratification based-tumor size and SUVmax for HER2 expression. Moreover, PFS was analyzed by Kaplan–Meier method and log-rank tests were used in univariate analysis. P values less than 0.05 were considered statistically significant, and all analyses were two sided.

Results

Patient characteristic

Among the 131 patients including 84 men and 47 women, the HER2 expression of primary lesions were 20.6% with positivity (19.8% with a score of 2 + and 0.8% with a score of 3+) and 79.4% with negativity (51.1% with a score of 0 and 28.3% with a score of 1+). 93 patients had well or moderately differentiated adenocarcinoma, 38 had poorly differentiated adenocarcinoma. Regarding lymph node metastasis, 62.6% samples (82/131) were detected as positive while 37.4% (49/131) as negative.

Relationship With Patient Characteristics And 18f-fdg Pet/ct Parameters

The SUVmax for the primary tumors ranged from 4.84 to 43.88. Table 1 demonstrated the relationships between the clinicopathologic parameters and SUVmax. Statistical analysis exhibited no significant differences in SUVmax according to sex, age, lymph node metastasis, T category, or location of tumor. However, there were significant differences in SUVmax according to tumor size ($p = 0.012$, Table 1). Tumor size which is bigger than 5 cm had a significantly higher SUVmax than did smaller than the base line. Tumor size ranged from 1.5 to 13.5 cm on pathological examination. Besides, no significant correlations were found between SUVmean, MTV, TLG and patient characteristics in colorectal cancer.

Table 1

The relationships between the clinicopathologic parameters and SUVmax

Variable	No.	SUVmax (Mean $\pm$ SD)	P
Sex			0.661
Male	84	15.416 $\pm$ 7.265	
Female	47	14.911 $\pm$ 7.189	
Age (y)			0.300
< 60	58	14.423 $\pm$ 6.457	
$\geq$ 60	73	15.880 $\pm$ 7.746	
Tumor size (cm)			0.012
< 5	93	14.418 $\pm$ 6.980	
$\geq$ 5	38	16.521 $\pm$ 6.736	
Lymph node metastasis			0.104
Negative	49	16.742 $\pm$ 8.000	
Positive	82	14.334 $\pm$ 6.588	
Histologic differentiate			0.598
Well or moderately	93	15.147 $\pm$ 7.493	
Poorly	38	15.451 $\pm$ 6.570	
HER2 status			0.034
Positive	27	18.238 $\pm$ 8.912	
Negative	104	14.455 $\pm$ 6.531	
T stage			0.889
T1/T2	36	15.689 $\pm$ 78.072	
T3/T4	95	15.063 $\pm$ 6.900	
Tumor location			0.526
Proximal	107	15.040 $\pm$ 7.079	
Distal	24	16.107 $\pm$ 7.889	
CEA level			0.540

Abbreviation: SD, standard deviation; T, tumor; CEA, carcino-embryonic antigen

Variable	No.	SUVmax (Mean ± SD)	P
< 5	64	15.262 ± 8.018	
≥ 5	67	15.209 ± 8.413	
Abbreviation: SD, standard deviation; T, tumor; CEA, carcino-embryonic antigen			

Correlation Between Patient Characteristics And Her2 Expression

Patients were categorized into 2 groups according to immunohistochemical staining for HER2: patients with HER2 expression (n = 27) and patients without HER2 expression (n = 104). Table 2 showed the results of the univariate analysis for each factor. No significant differences in sex, age, lymph node metastasis, or T category were found between the two groups. However, the differences between the size of the primary tumor and the HER2 expression were statistically significant (34.2% vs. 15.1%; p = 0.014). The bigger primary tumor had a higher rate of HER2 positivity than smaller ones.

Table 2
The univariate analysis for HER2 expression

Variable	No.	HER2(-)	HER2(+)	χ^2	P
Sex				1.464	0.226
Male	84	64	20		
Female	47	40	7		
Age (y)				1.650	0.199
< 60	58	49	9		
≥ 60	73	55	18		
Tumor size (cm)				6.050	0.014
< 5	93	79	14		
≥ 5	38	25	13		
Lymph node metastasis				0.002	0.965
Negative	49	39	10		
Positive	82	65	17		
Histologic differentiate				0.309	0.578
Well- or moderately	93	75	18		
Poorly	38	29	9		
T stage				1.558	0.212
T1/T2	36	26	10		
T3/T4	95	78	17		
Tumor location				0.001	0.976
Proximal	107	85	22		
Distal	24	19	5		
CEA level				1.473	0.225
< 5	64	48	16		
≥ 5	67	56	11		
Abbreviation: T, tumor; CEA, carcino-embryonic antigen.					

Indicators For Her2 Expression

Mann–Whitney U test analysis revealed that patients with HER2-positive had a significantly higher SUVmax than HER2-negative group (18.238 ± 8.912 vs. 14.455 ± 6.531 ; $p = 0.034$, Fig. 1). Additionally, HER2 status has no connection to SUVmean, MTV or TLG in our study. Multivariate analysis revealed that SUVmax and tumor size correlated significantly with HER2 expression in colorectal cancer ($p = 0.049$ VS $p = 0.043$, respectively; Table 3). Therefore, using these parameters, we categorized the patients into groups based on their potential of being HER2-positive: a low-potential group (sizes < 5 cm and SUVmax < 12.69), a moderate-potential group (sizes ≥ 5 cm and SUVmax < 12.69 , or sizes < 5 cm and SUVmax ≥ 12.69), and a high-potential group (sizes ≥ 5 cm and SUVmax ≥ 12.69). The probability of HER2 expression in these groups was 13.2%, 17.6%, and 40.7%, respectively ($p = 0.013$; Table 4). These results suggest that ^{18}F -FDG PET/CT scans can be useful for predicting the HER2 status of colorectal cancer. A cut-off level was determined by the median SUVmax.

Table 3
Multivariate analysis for HER2 expression

	P	Odds Ratio	95% CI
Tumor size	0.043	2.533	1.031–6.224
SUVmax	0.049	1.060	1.000–1.123
Abbreviation: CI, Confidence interval			

Table 4
Stratification based-tumor size and SUVmax for predicting HER2 expression

Stratification	No (%)	HER2(%)		P
		(-)	(+)	
Low	53 (40.5%)	46(35.1%)	7(5.4%)	0.013
Moderate	51 (38.9%)	42(32.1%)	9(6.8%)	
High	27 (20.6%)	16(12.2%)	11(8.4%)	
Total	131 (100%)	104(79.4%)	27(20.6%)	

Prognosis

Univariate analyses were performed to investigate the predictive and prognostic value of PET/CT parameters. When the optimal cutoff value for PFS was determined by median SUVmax (cutoff = 12.69), Kaplan Meier regression shows that the differences between SUVmax and the PFS of patients were

statistically significant ($p = 0.029$, Fig. 2). Patients with higher SUVmax had significantly longer median PFS than ones with lower SUVmax (cutoff = 12.69, $n = 67$ vs 64, 17 vs 13 months, respectively).

When the optimal cutoff value for PFS was determined by the sizes of primary tumors, there's no differences between SUVmax and the PFS of patients ($p = 0.168$). In terms of HER2 expression, the PFS of patients with HER2-positive group was not statistically different from that of HER2-negative group ($p = 0.280$). However, the HER2-positive patients did have longer median PFS than that of the HER2-negative ones (16 vs 19 months), although not significantly different.

Discussion

The HERACLES-A and MyPathway studies have shown benefit in a small number of patients with the use of combination trastuzumab-lapatinib and trastuzumab-pertuzumab, respectively(9, 10). Testing for HER2 expression is currently a practice in the management of colorectal cancer. However, the positive rate of HER2 in colorectal cancer is not consistent in domestic and foreign literature reports. Our study demonstrated a 20.6% rate of HER2 expression. PET/CT is a molecular imaging technique widely used in the diagnosis and staging of malignant tumors. Our results showed that the SUVmax in colorectal cancer was significantly higher when HER2 was expressed than when not expressed. Besides, SUVmax and the PFS of patients have significantly statistical differences. To our knowledge, this was the first study to analyze the association between HER2 expression and predictive value of ^{18}F -FDG PET/CT parameters in colorectal cancer patients.

Our data also demonstrated that HER2 expression is more common in big primary tumor size than in small size. This finding is similar to the findings of previous studies(19). In addition, big primary tumor had significantly higher ^{18}F -FDG uptake than did small primary tumor, partly explaining why patients with HER2 expression had a high SUVmax. But the reasons for this selective high rate of HER2 expression in big primary tumor sizes remain unclear. Multivariate analysis revealed that both the SUVmax of the primary tumor and the tumor size correlated significantly with HER2 expression. We further categorized patients into groups based on their potential for being HER2-positive: high-potential, moderate-potential, and low-potential. HER2 was expressed in 40.7% of the high-potential group while in 13.2% of the low-potential group, implying that anti-HER2 therapies are not effective for patients with a low potential of being HER2-positive. For these reasons, noninvasive methods, such as molecular imaging, for predicting HER2 status have great clinical relevance. In our study, SUVmax has the independently potential to evaluate the HER2 status in colorectal carcinoma with metastatic lesions. Meanwhile, SUVmax united to the sizes of the primary tumors can also precisely forecast the HER2 expression in colorectal cancer.

The “Trastuzumab for Gastric Cancer” trial on metastatic gastric cancer demonstrated a significant overall survival benefit when trastuzumab was combined with chemotherapy(20). HER2 status is routinely used to predict the efficacy of anti-HER2 therapies. Actually, the role of HER2 as a prognostic factor in colorectal cancer had been controversial(21). the HERACLES-A and MyPathway studies demonstrated that patients with HER2 amplification did not derive a survival benefit from chemoradiation

therapy whereas patients without HER2 amplification derived a statistically significant survival benefit. Some studies failed to find an association with prognosis(22, 23), whereas others found a direct correlation between HER2 expression or amplification and poor survival(24, 25). In our study, there's no significantly statistical difference between HER2 expression and the PFS of patients, we could attribute this result to the lack of anti-HER2 therapies on the selected patients. In a future study, we intend to collect specific anti-HER2 therapy cases to elucidate the correlations between HER2 expression, progression free survival, and the 18F-FDG uptake of anti-HER2 therapy patients. The present data shows that patients with higher SUVmax had longer median PFS than ones with lower SUVmax. This result is not similar to many studies(26, 27). The reasons of such a result are not very clear. Data bias cannot be excluded. Another reason we speculated is that the higher FDG uptake may indicate the more sensitive therapeutic effect. But it needs more correlational studies to prove this assumption.

This study was partly limited by its retrospective design and no HER2-targeted molecular therapies. Although PET/CT may have a moderate diagnostic performance, as we all know, it cannot replace conventional methods in the clinical setting. Nonetheless, our results may be relevant for the development of noninvasive strategies to predict prognosis and HER2 expression in colorectal cancer patients. Advances in PET radiotracers may increase the sensitivity and specificity of this technique and enable full molecular assessment of colorectal cancer.

Conclusions

¹⁸F-FDG PET/CT was a potential predictor for HER2 expression status in colorectal cancer, and patients with HER2-positive expression shows higher FDG uptake. Combination with primary tumor size, SUVmax showed more predictive efficiency for HER2 expression. Our study potentially contributed to anti-HER2 target therapy in inoperable advanced colorectal cancer patients by evaluating HER2 expression of tumor noninvasively.

Abbreviations

¹⁸F-FDG, 18fluor-fluoro-deoxy-glucose

PET/ CT, Positron emission tomography/ Computed tomography

SUV, standard uptake value-based

SUVmax, Maximum standard uptake value

SUVmean, Mean standard uptake value

TLG, Total lesion glycolysis

MTV, Metabolic tumor volume

CRC, Colorectal cancer

HER2, Human epidermal growth factor receptor 2

PFS, Progression-free survival

CI, Confidence interval

Declarations

Ethical approval

All procedures performed in studies involving human participants were approved by the Institutional Review Board of Fudan university Shanghai cancer center and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This article does not describe any studies with animals performed by any of the authors.

Consent for publication

Not applicable.

Availability of data and material

Please contact corresponding author for data requests.

Funding

This study was supported by the National Natural Science Foundation of China (No.81771861) and Shanghai Scientific and Technological Innovation Program (No.18410711200) for Shaoli Song.

Authors' contributions

Shaoli Song designed this study. The data was supported by Ziyi Yang, Shuai Liu, Yuyun Sun, Junyan Xu, Jinjin Jiang, Xiaoxi Ma and Yingjian Zhang. Ziyi Yang analysed all data, discussed results and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgments

We are very grateful for the funding supported by National Natural Science Foundation of China (No. 81771861), and Shanghai Science and Technology Commission Projects for International Cooperation (No. 18410711200), and Foundation of Shanghai Municipal Commission of Health and Family Planning (No. 20170425).

Conflict of Interest Statement

The author declared they had no conflict of interest.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA: a cancer journal for clinicians*. 2018;68(1):7-30.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA: a cancer journal for clinicians*. 2016;66(1):7-30.
3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. *CA: a cancer journal for clinicians*. 2016;66(2):115-32.
4. Van Cutsem E, Oliveira J. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2009;20 Suppl 4:61-3.
5. Najib S, Kowalski-Chauvel A, Do C, Roche S, Cohen-Jonathan-Moyal E, Seva C. Progastrin a new pro-angiogenic factor in colorectal cancer. *Oncogene*. 2015;34(24):3120-30.
6. Marx AH, Burandt EC, Choschzick M, Simon R, Yekebas E, Kaifi JT, et al. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. *Hum Pathol*. 2010;41(11):1577-85.
7. Park DI, Kang MS, Oh SJ, Kim HJ, Cho YK, Sohn CI, et al. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. *International journal of colorectal disease*. 2007;22(5):491-7.
8. Seo AN, Kwak Y, Kim DW, Kang SB, Choe G, Kim WH, et al. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. *PloS one*. 2014;9(5):e98528.
9. Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. *The Lancet Oncology*. 2016;17(6):738-46.
10. Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, et al. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2018;36(6):536-42.
11. Chen R, Zhou X, Liu J, Huang G. Relationship Between 18F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 2016;57(7):1040-4.
12. Caicedo C, Garcia-Velloso MJ, Lozano MD, Labiano T, Vigil Diaz C, Lopez-Picazo JM, et al. Role of [(1)(8)F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer. *European journal of nuclear medicine and molecular imaging*. 2014;41(11):2058-65.
13. Kawada K, Nakamoto Y, Kawada M, Hida K, Matsumoto T, Murakami T, et al. Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer. *Clinical*

cancer research : an official journal of the American Association for Cancer Research. 2012;18(6):1696-703.

14. Kawada K, Toda K, Nakamoto Y, Iwamoto M, Hatano E, Chen F, et al. Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 2015;56(9):1322-7.
15. Sachpekidis C, Larribere L, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A, Hassel JC. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. *European journal of nuclear medicine and molecular imaging*. 2015;42(3):386-96.
16. Garcia Vicente AM, Soriano Castrejon A, Lopez-Fidalgo JF, Amo-Salas M, Munoz Sanchez Mdel M, Alvarez Cabellos R, et al. Basal (1)(8)F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography as a prognostic biomarker in patients with locally advanced breast cancer. *European journal of nuclear medicine and molecular imaging*. 2015;42(12):1804-13.
17. Herreros-Villanueva M, Rodrigo M, Claver M, Muniz P, Lastra E, Garcia-Giron C, et al. KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. *Molecular biology reports*. 2011;38(2):1315-20.
18. Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H, et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*. 2004;17(8):895-904.
19. Seo AN, Kwak Y, Kim WH, Kim DW, Kang SB, Choe G, et al. HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value. *Virchows Archiv : an international journal of pathology*. 2015;466(6):645-54.
20. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet (London, England)*. 2010;376(9742):687-97.
21. Takegawa N, Yonesaka K. HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy. *Clinical colorectal cancer*. 2017;16(4):247-51.
22. He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, et al. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. *World journal of gastroenterology*. 2013;19(14):2171-8.
23. Tateishi M, Toda T, Minamisono Y, Nagasaki S. Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. *Journal of surgical oncology*. 1992;49(4):209-12.
24. Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. *Annals of surgical oncology*. 2011;18(10):2833-40.

25. Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, da Costa WL, Jr., et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2011;29(22):3030-6.
26. Groheux D, Sanna A, Majdoub M, de Cremoux P, Giacchetti S, Teixeira L, et al. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 2015;56(6):824-31.
27. Hsieh CE, Ho KC, Hsieh CH, Yen TC, Liao CT, Wang HM, et al. Pretreatment Primary Tumor SUVmax on 18F-FDG PET/CT Images Predicts Outcomes in Patients With Salivary Gland Carcinoma Treated With Definitive Intensity-Modulated Radiation Therapy. *Clinical nuclear medicine*. 2017;42(9):655-62.

Figures

Figure 1

Representative PET/CT images. A 49-year-old male patient with HER2-positive rectal cancer. Axial computed tomography (CT, Fig 1A) showed a thickened rectal wall (red arrow) and a corresponding focal FDG uptake in the PET scan (Fig 1B-D). The maximum standard uptake value (SUVmax) was 13.77 (red arrow). After surgery, immunohistochemical (IHC) staining showed that the tumour had a positive HER2 status, as shown in Fig 1C.

Figure 2

Representative PET/CT images. A 49-year-old female patient with HER2-negative rectal cancer. The primary tumour had a lower radio-uptake (SUVmax=9.1, Fig 2B-D, CT scan; Fig 2A; Fig 1F, IHC).

Figure 3

Postoperative IHC. The two 49-year-old patients with HER2 status (HER2-positive, Fig 3A; HER2-negative, Fig 3B).

Figure 4

The correlation between SUVmax and PFS. The cutoff of SUVmax for PFS was 12.69. Patients with a higher SUVmax had a longer PFS than those with a lower SUVmax ($p = 0.029$).